Advanced biomarkers: Beyond amyloid and tau: Emerging non-traditional biomarkers for alzheimer`s diagnosis and progression
- 22 March 2025
- journal article
- review article
- Published by Elsevier in Ageing Research Reviews
- Vol. 108, 102736
Abstract
No abstract availableKeywords
This publication has 101 references indexed in Scilit:
- Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary CareJAMA, 2024
- Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's diseaseAlzheimer's & Dementia, 2024
- Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkersAlzheimer's & Dementia, 2024
- Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 yearsAlzheimer's & Dementia, 2022
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumJAMA Neurology, 2021
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in NeurologyJAMA Neurology, 2019
- Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer DiseaseJAMA Neurology, 2019
- CSF neurogranin or tau distinguish typical and atypical Alzheimer diseaseAnnals of Clinical and Translational Neurology, 2018
- Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer DiseaseJAMA Neurology, 2015
- Developing a simple laboratory test for Alzheimer's disease: measuring acetylcholinesterase in saliva ‐ a pilot studyInternational Journal of Geriatric Psychiatry, 2007